Presentations & Publications

Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation

UPLOADED:

November 13, 2017

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer-antigenspecific T cell responses in patients with metastatic castration-resistant prostate cancer

UPLOADED:

November 13, 2017

Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation

UPLOADED:

November 13, 2017

Baseline serum protein levels associated with survival in axalimogene filolisbac (AXAL)-treated metastatic cervical cancer patients: The GOG/NRG-0265 trial

UPLOADED:

November 1, 2017

Persistence of expanded TCRß clonotypes is associated with clinical activity of ADXS-PSA immunotherapy in metastatic castration-resistant prostate cancer

UPLOADED:

September 9, 2017

Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model

UPLOADED:

September 9, 2017

Gene expression profiles associated with stable disease in metastatic castration resistant prostate cancer patients treated with ADXS-PSA immunotherapy

UPLOADED:

September 9, 2017

Therapeutic options for treatment of human papillomavirus-associated cancers – novel immunologic vaccines: ADXS11–001

UPLOADED:

July 14, 2017

Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy

UPLOADED:

June 29, 2017

2017 Investor Analyst Day

UPLOADED:

June 12, 2017

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.